or
forgot password
  • cancer clinical trials in commack, NY

  • Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Non Hodgkin Lymphoma (NHL), Diffuse Large B-cell Lymphoma (DLBCL)
    Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Non-Small Cell Lung Cancer
    Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Non-small Cell Lung Cancer
    Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Invasive Breast Cancer
    Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Relapsed or Refractory Multiple Myeloma
    Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
    Memorial Sloan-Kettering Cancer Center at Commack
    Commack, New York 11725
    Thyroid Cancer
    Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
    Memorial Sloan-Kettering Cancer Center at Suffolk
    Commack, New York 11725
    Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
    Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Stomach Neoplasms, Esophageal Neoplasms
    Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Myeloproliferative Disorder, Urothelial Carcinoma, Cancer
    Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors
    Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
    Memorial Sloan-Kettering Cancer Center at Commack
    Commack, New York 11725
    Head and Neck, Squamous Cell Cancer
    Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Lung Adenocarcinoma
    Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer
    Memorial Sloan-Kettering Cancer Center at Commack
    Commack, New York 11725
    Lung Cancer
    Survey and Blood Sample Collection for Patients With Lung Cancer Who Never Smoked Cigarettes
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Lung Cancer
    Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Colon Cancer
    Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
    Memorial Sloan-Kettering Cancer Center @ Suffolk
    Commack, New York 11725
    Bladder Cancer, Urinary Bladder
    Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors
    Long Island Brain Tumor Center at Neurological Surgery PC / Long Island Neuro-Oncology Associates
    Commack, New York 11725
    Recurrent Malignant Gliomas